<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083070</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0411</org_study_id>
    <secondary_id>CDR0000362059</secondary_id>
    <secondary_id>COG-ADVL0411</secondary_id>
    <nct_id>NCT00083070</nct_id>
  </id_info>
  <brief_title>Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia</brief_title>
  <official_title>A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop&#xD;
      cancer cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide in&#xD;
      treating young patients with refractory or recurrent leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of temozolomide in&#xD;
           pediatric patients with refractory or recurrent leukemia.&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the antitumor activity of this drug in these patients.&#xD;
&#xD;
        -  Determine the biologic activity and mechanism(s) of resistance to this drug in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days&#xD;
      for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and recommended phase II dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as assessed by CTCAE 3.0</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics as assessed by CI, area under the curve (AUC), and half-life (T ½)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic activity and mechanisms of resistance</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Temozolomide Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>Temozolomide Therapy</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>NSC # 362856</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed leukemia of any of the following types:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia in blast crisis&#xD;
&#xD;
          -  Refractory or recurrent disease&#xD;
&#xD;
          -  Immunophenotypic confirmation of disease at initial diagnosis or recurrence&#xD;
&#xD;
          -  More than 25% blasts in the bone marrow (M3)&#xD;
&#xD;
          -  Active extramedullary disease allowed except for leptomeningeal disease&#xD;
&#xD;
          -  No known curative therapy or therapy proven to prolong survival with an acceptable&#xD;
             quality of life&#xD;
&#xD;
          -  No active CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  1 to 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100% (for patients &gt; 10 years of age)&#xD;
&#xD;
          -  Lansky 50-100% (for patients ≤ 10 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &lt; 30,000/mm^3 (hydroxyurea or leukapheresis allowed at the discretion of the&#xD;
             principal investigator)&#xD;
&#xD;
          -  Platelet count ≥ 20,000/mm^3 (platelet transfusions allowed)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (red blood cell transfusions allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal for age OR&#xD;
&#xD;
          -  Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min/1.73 m^2&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 7 days since prior biologic therapy, including immunotherapy&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation&#xD;
&#xD;
               -  No evidence of active graft-vs-host disease&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  Prior therapy with hydroxyurea allowed for up to 24 hours before initiation of study&#xD;
             drug&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent hydrocortisone or other corticosteroids allowed as premedications prior to&#xD;
             blood product transfusions in patients with prior severe allergic reactions&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terzah M. Horton, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Texas Children's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center at Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview University Medical Center - University Campus</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-9786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM; Children's Oncology Group Study. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 1;25(31):4922-8.</citation>
    <PMID>17971589</PMID>
  </results_reference>
  <results_reference>
    <citation>Horton TM, Dolan E, Hegde M, et al.: A phase I study of temozolomide (Temodar®) in pediatric patients with relapsed or refractory leukemia: a Children's Oncology Group study. [Abstract] Blood 106 (11): A-4455, 2005.</citation>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

